BIOTISSUE OCULAR INC.
MIAMI, FLORIDA

BIOTISSUE OCULAR INC., founded in 1997, is a pioneering company specializing in ocular surface and lid margin diseases through innovative regenerative healing products. The firm prides itself on producing items that adhere to the highest clinical standards, grounded in rigorous research and scientific data. Over three decades, Bio-Tissue has dedicated itself to enhancing patient quality of life by providing solutions aimed at healthy eyes and improved vision. The company utilizes process technologies such as the CryoTek™ Method for preserving amniotic membrane's natural wound healing properties, positioning it as a standard in ocular surface reconstruction. Notable figures like Amy have driven Bio-Tissue's growth through visionary leadership since its inception, while also ensuring outstanding product quality and advances in wound care management techniques. Dr. Scheffer C. G. Tseng brings distinguished expertise with academic credentials from National Taiwan University and the University of California, emphasizing his contributions to corneal health advancements. Financially, Michael Cornelius, an adept executive with a strong background at Stiefel Laboratories, currently serves as CFO, further solidifying the company's fiscal stability. With a clear vision to become the leader in regenerative biomaterials, Bio-Tissue aims for scientific breakthroughs and commercial growth, maintaining its position among the top contenders over the next five years. Its strategic business directions include fostering innovation through products like Cliradex towelettes and foaming cleansers designed for eyecare hygiene. Recognized by medical professionals as a premier solution for ocular care, Bio-Tissue continues to make significant impacts in its field while adhering to principles such as placing patients first and respecting mutual growth. The company's commitment is reflected in its strategic vision and mission towards developing human-origin regenerative biomaterials.